Syndecan-1 inhibition promotes anti-tumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy (kdSdc1 and mutant)

To investigate the function of SDC1 in the regulation of anti-tumor immunity, we established B16 and MC38 cell lines in which sdc1 or control RNA has been knocked down by shRNA. Comparative gene expression profiling analysis of RNA-seq data for B16 and MC38 cell lines representing sdc1 knockdown, sdc1 knockdown+c30 mutant, sdc1 knockdown+ect mutant, sdc1 knockdown+sdc1 wt, that were stimulated with IFNr.